Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
1.
Eur J Neurol ; 27(12): 2625-2629, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32810878

RESUMO

BACKGROUND AND PURPOSE: There is a lack of comparative safety data on the risk of pseudotumor cerebri syndrome (PTCS) associated with different hormonal contraceptives. We sought to quantify the risk of PTCS associated with eight different types of hormonal contraceptives compared with oral levonorgestrel. METHODS: We conducted a retrospective cohort study, with a case-control analysis of 4 871 504 women aged 15-45 years in the period 2008-2015, using IQVIA Ambulatory Electronic Medical Records data in the USA. Patients who used nine different contraceptive agents including intrauterine levonorgestrel, medroxyprogesterone injection, etonogestrel/ethinyl estradiol vaginal ring and combination oral contraceptives (COCs) that contained ethinyl estradiol and the progestins levonorgestrel, norgestimate, desogestrel, norethindrone and drospirenone, were included. Diagnosis of PTCS was defined using the first International Classification of Diseases, 9th or 10th revision, code for intracranial hypertension in patients who had also received an imaging code in the 30 days prior to the index date. RESULTS: A total of 3323 PTCS cases and 13 292 matched controls were identified. No increase in risk was found when analysing intrauterine levonorgestrel or COCs containing desogestrel, norethindrone, drospirenone, norgestimate or norgestrel versus COC levonorgestrel. The adjusted incidence rate ratio for etonogestrel/etonogestrel/ethinyl estradiol vaginal ring and medroxyprogesterone suspension compared with levonorgestrel COC was 4.45 [95% confidence interval (CI) 1.98-9.96] and 2.20 (95% CI 1.33-3.64), respectively. CONCLUSIONS: This study found an elevated risk for PTCS among users of etonogestrel vaginal ring and medroxyprogesterone suspension when compared with oral levonorgestrel. Future studies are needed to confirm these findings.


Assuntos
Pseudotumor Cerebral , Adolescente , Adulto , Anticoncepcionais Orais Combinados , Anticoncepcionais Orais Hormonais/efeitos adversos , Feminino , Humanos , Levanogestrel/efeitos adversos , Pessoa de Meia-Idade , Pseudotumor Cerebral/induzido quimicamente , Pseudotumor Cerebral/epidemiologia , Estudos Retrospectivos , Adulto Jovem
2.
Pharmacogenomics J ; 18(1): 187-195, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-27779249

RESUMO

Differences in response to medications have a strong genetic component. By leveraging publically available data, the spectrum of such genomic variation can be investigated extensively. Pharmacogenomic variation was extracted from the 1000 Genomes Project Phase 3 data (2504 individuals, 26 global populations). A total of 12 084 genetic variants were found in 120 pharmacogenes, with the majority (90.0%) classified as rare variants (global minor allele frequency <0.5%), with 52.9% being singletons. Common variation clustered individuals into continental super-populations and 23 pharmacogenes contained highly differentiated variants (FST>0.5) for one or more super-population comparison. A median of three clinical variants (PharmGKB level 1A/B) was found per individual, and 55.4% of individuals carried loss-of-function variants, varying by super-population (East Asian 60.9%>African 60.1%>South Asian 60.3%>European 49.3%>Admixed 39.2%). Genome sequencing can therefore identify clinical pharmacogenomic variation, and future studies need to consider rare variation to understand the spectrum of genetic diversity contributing to drug response.


Assuntos
Variação Genética/genética , Proteínas/genética , Alelos , Etnicidade/genética , Frequência do Gene/genética , Genética Populacional/métodos , Humanos , Farmacogenética/métodos
3.
Pharmacogenomics J ; 15(5): 430-5, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25752520

RESUMO

The objective of this study was to examine interindividual variability in codeine requirements and pain management by examining select genetic polymorphisms in the codeine pharmacological pathway. The study included a nested cohort of 98 women who were prescribed codeine following cesarean section. Participants were genotyped for select polymorphisms of the COMT, ABCB1, CYP2D6, UGT2B7 and OPRM1 genes and instructed to describe their level of pain using the visual analog scale (mm) 1 h following each dose of codeine. Analysis revealed that reported pain increases with maternal age (P=0.041). Asians required more codeine than Caucasians (P=0.048). Significant differences in mean dose consumption were seen among the genotypic groups of the OPRM1 A118G (P=0.001) and UGT2B7 C802T (P=0.015) variants. These variants were found to predict codeine consumption in the cohort overall (P=0.000) and among Caucasians (P=0.001). These findings will assist in customizing therapy to effectively manage postpartum pain.


Assuntos
Codeína/administração & dosagem , Glucuronosiltransferase/genética , Dor/genética , Receptores Opioides mu/genética , Adulto , Cesárea/efeitos adversos , Feminino , Genótipo , Humanos , Dor/tratamento farmacológico , Dor/patologia , Manejo da Dor , Farmacogenética , Polimorfismo de Nucleotídeo Único , Período Pós-Parto , Gravidez
4.
Pharmacogenomics J ; 14(2): 160-70, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23588107

RESUMO

There is established clinical evidence for differences in drug response, cure rates and survival outcomes between different ethnic populations, but the causes are poorly understood. Differences in frequencies of functional genetic variants in key drug response and metabolism genes may significantly influence drug response differences in different populations. To assess this, we genotyped 1330 individuals of African (n=372) and European (n=958) descent for 4535 single-nucleotide polymorphisms in 350 key drug absorption, distribution, metabolism, elimination and toxicity genes. Important and remarkable differences in the distribution of genetic variants were observed between Africans and Europeans and among the African populations. These could translate into significant differences in drug efficacy and safety profiles, and also in the required dose to achieve the desired therapeutic effect in different populations. Our data points to the need for population-specific genetic variation in personalizing medicine and care.


Assuntos
Síndrome da Imunodeficiência Adquirida/genética , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética , Neoplasias/genética , Tuberculose/genética , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/patologia , População Negra/genética , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Frequência do Gene , Predisposição Genética para Doença , Variação Genética , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/patologia , Polimorfismo de Nucleotídeo Único , Tuberculose/tratamento farmacológico , Tuberculose/patologia , População Branca/genética
5.
Pharmacogenomics J ; 14(6): 555-63, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24861855

RESUMO

Differences in the frequency of pharmacogenomic variants may influence inter-population variability in drug efficacy and risk of adverse drug reactions (ADRs). We investigated the diversity of ∼ 4500 genetic variants in key drug-biotransformation and -response genes among three South East Asian populations compared with individuals of European ancestry. We compared rates of reported ADRs in these Asian populations to determine if the allelic differentiation corresponded to an excess of the associated ADR. We identified an excess of ADRs related to clopidogrel in Singaporean Chinese, consistent with a higher frequency of a known risk variant in CYP2C19 in that population. We also observed an excess of ADRs related to platinum compounds in Singaporean CHS, despite a very low frequency of known ADR risk variants, suggesting the presence of additional genetic and non-genetic risk factors. Our results point to substantial diversity at specific pharmacogenomic loci that may contribute to inter-population variability in drug response phenotypes.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Variação Genética/genética , Biotransformação , Europa (Continente) , Humanos , Singapura
6.
Clin Genet ; 86(1): 21-8, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24684508

RESUMO

The vast range of genetic diversity contributes to a wonderful array of human traits and characteristics. Unfortunately, a consequence of this genetic diversity is large variability in drug response between people, meaning that no single medication is safe and effective in everyone. The debilitating and sometimes deadly consequences of adverse drug reactions (ADRs) are a major and unmet problem of modern medicine. Pharmacogenomics can uncover associations between genetic variation and drug safety and has the potential to predict ADRs in individual patients. Here we review pharmacogenomic successes leading to changes in clinical practice, as well as clinical areas probably to be impacted by pharmacogenomics in the near future. We also discuss some of the challenges, and potential solutions, that remain for the implementation of pharmacogenomic testing into clinical practice for the significant improvement of drug safety.


Assuntos
Biomarcadores Farmacológicos , Testes Genéticos/métodos , Variação Genética , Farmacogenética/métodos , Farmacogenética/tendências , Medicina de Precisão/métodos , Antraciclinas/farmacologia , Carbamazepina/farmacologia , Cisplatino/farmacologia , Codeína/farmacologia , Humanos , Medicina de Precisão/tendências , Varfarina/farmacologia
7.
Pediatr Blood Cancer ; 60(8): 1375-81, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23441093

RESUMO

BACKGROUND: The use of anthracyclines as effective antineoplastic drugs is limited by the occurrence of cardiotoxicity. Multiple genetic variants predictive of anthracycline-induced cardiotoxicity (ACT) in children were recently identified. The current study was aimed to assess replication of these findings in an independent cohort of children. PROCEDURE: . Twenty-three variants were tested for association with ACT in an independent cohort of 218 patients. Predictive models including genetic and clinical risk factors were constructed in the original cohort and assessed in the current replication cohort. RESULTS: . We confirmed the association of rs17863783 in UGT1A6 and ACT in the replication cohort (P = 0.0062, odds ratio (OR) 7.98). Additional evidence for association of rs7853758 (P = 0.058, OR 0.46) and rs885004 (P = 0.058, OR 0.42) in SLC28A3 was found (combined P = 1.6 × 10(-5) and P = 3.0 × 10(-5), respectively). A previously constructed prediction model did not significantly improve risk prediction in the replication cohort over clinical factors alone. However, an improved prediction model constructed using replicated genetic variants as well as clinical factors discriminated significantly better between cases and controls than clinical factors alone in both original (AUC 0.77 vs. 0.68, P = 0.0031) and replication cohort (AUC 0.77 vs. 0.69, P = 0.060). CONCLUSIONS: . We validated genetic variants in two genes predictive of ACT in an independent cohort. A prediction model combining replicated genetic variants as well as clinical risk factors might be able to identify high- and low-risk patients who could benefit from alternative treatment options.


Assuntos
Antraciclinas/efeitos adversos , Antineoplásicos/efeitos adversos , Cardiotoxinas/efeitos adversos , Doenças Cardiovasculares/genética , Glucuronosiltransferase/genética , Proteínas de Membrana Transportadoras/genética , Modelos Biológicos , Polimorfismo de Nucleotídeo Único , Adolescente , Antraciclinas/administração & dosagem , Antineoplásicos/administração & dosagem , Cardiotoxinas/administração & dosagem , Doenças Cardiovasculares/induzido quimicamente , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Marcadores Genéticos , Humanos , Lactente , Masculino , Neoplasias/tratamento farmacológico , Neoplasias/genética , Valor Preditivo dos Testes
8.
Pharmacogenomics J ; 12(3): 205-13, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21502965

RESUMO

Cisplatin is a widely used chemotherapy drug in the treatment of pediatric solid tumors, but it is associated with significant rates of ototoxicity (medication-induced hearing loss). A genetic test has recently been developed that can help predict the likelihood that a cisplatin-treated pediatric patient will develop ototoxicity. This study estimates the potential economic impact of this test. Assuming that an alternative, non-preferred, medication to cisplatin exists that it is as efficacious as cisplatin but without the risk of hearing loss, and that the alternative treatment is no more expensive than current practice, we have estimated that administering this genetic test to every pediatric cancer patient for whom cisplatin is first-line therapy could potentially avoid an average of $71,168 in societal costs per tested patient. This translates into a potential present value savings of over $2.4 million annually in British Columbia and over $19.6 million in Canada.


Assuntos
Antineoplásicos/efeitos adversos , Antineoplásicos/economia , Cisplatino/efeitos adversos , Cisplatino/economia , Testes Genéticos/economia , Custos de Cuidados de Saúde , Perda Auditiva/economia , Perda Auditiva/genética , Farmacogenética/economia , Adolescente , Adulto , Fatores Etários , Canadá , Criança , Pré-Escolar , Redução de Custos , Custos de Medicamentos , Predisposição Genética para Doença , Perda Auditiva/induzido quimicamente , Perda Auditiva/prevenção & controle , Humanos , Pessoa de Meia-Idade , Modelos Econômicos , Medição de Risco , Fatores de Risco , Adulto Jovem
9.
Pharmacogenomics J ; 12(3): 233-7, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21243006

RESUMO

Statins reduce cardiovascular morbidity and mortality in appropriately selected patients. However, statin-associated myopathy is a significant risk associated with these agents. Recently, variation in the SLCO1B1 gene was reported to predict simvastatin-associated myopathy. The aim of this study was to replicate association of the rs4149056 variant in SLCO1B1 with severe statin-associated myopathy in a cohort of patients using a variety of statin medications and to investigate the association with specific statin types. We identified 25 cases of severe statin-associated myopathy and 84 controls matched for age, gender, statin type and dose. The rs4149056 variant in SLCO1B1 was not significantly associated with myopathy in this group as a whole. However, when subjects were stratified by statin type, the SLCO1B1 rs4149056 genotype was significantly associated with myopathy in patients who received simvastatin, but not in patients who received atorvastatin. Our findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin.


Assuntos
Ácidos Heptanoicos/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Doenças Musculares/induzido quimicamente , Doenças Musculares/genética , Transportadores de Ânions Orgânicos/genética , Polimorfismo de Nucleotídeo Único , Pirróis/efeitos adversos , Sinvastatina/efeitos adversos , Adulto , Idoso , Atorvastatina , Colúmbia Britânica , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Feminino , Frequência do Gene , Predisposição Genética para Doença , Humanos , Transportador 1 de Ânion Orgânico Específico do Fígado , Masculino , Pessoa de Meia-Idade , Países Baixos , Razão de Chances , Fenótipo , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença
10.
BJOG ; 118(5): 624-8, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21392225

RESUMO

Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011;118:624-628. Currently, there is no effective therapy for severe early-onset intrauterine growth restriction (IUGR). Sildenafil citrate vasodilates the myometrial arteries isolated from women with IUGR-complicated pregnancies. Women were offered Sildenafil (25 mg three times daily until delivery) if their pregnancy was complicated by early-onset IUGR [abdominal circumference (AC)< 5th percentile] and either the gestational age was <25(+0) weeks or an estimate of the fetal weight was <600 g (excluding known fetal anomaly/syndrome and/or planned termination). Sildenafil treatment was associated with increased fetal AC growth [odds ratio, 12.9; 95% confidence interval (CI), 1.3, 126; compared with institutional Sildenafil-naive early-onset IUGR controls]. Randomised controlled trial data are required to determine whether Sildenafil improves perinatal outcomes for early-onset IUGR-complicated pregnancies.


Assuntos
Retardo do Crescimento Fetal/tratamento farmacológico , Piperazinas/uso terapêutico , Sulfonas/uso terapêutico , Vasodilatadores/uso terapêutico , Adulto , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Estudos de Casos e Controles , Feminino , Retardo do Crescimento Fetal/mortalidade , Retardo do Crescimento Fetal/fisiopatologia , Humanos , Recém-Nascido , Mortalidade Perinatal , Placenta/irrigação sanguínea , Gravidez , Resultado da Gravidez , Purinas/uso terapêutico , Citrato de Sildenafila , Útero/irrigação sanguínea
11.
Chronic Dis Can ; 30(2): 46-55, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20302685

RESUMO

To date there has been little investigation of the prevalence of comorbid conditions in asthma patients. Using 1996/97 cross-sectional health services administrative data for British Columbia, we compared the prevalence of comorbid conditions in treated adult asthma patients with the general adult population using a standardized comorbidity identification methodology, the Adjusted Clinical Group (ACG) Case-Mix System. We also profiled the comorbidity burden of pediatric asthma patients. Adults with asthma were significantly more likely to have a range of comorbidities, including respiratory infections, allergic rhinitis and 8 high impact/high prevalence chronic conditions (HIHPCCs). One in 4 adults with asthma had depression, the most prevalent HIHPCC. Children with asthma had a lower comorbidity burden than adults, but 12.6% had a stable or unstable chronic medical condition, with the most prevalent HIHPCC also depression. Adults with asthma had a high and complex comorbidity burden, particularly in terms of multiple chronic conditions. We discuss the implications for services planning and delivery.


Assuntos
Asma/epidemiologia , Adolescente , Adulto , Idoso , Algoritmos , Asma/terapia , Colúmbia Britânica , Criança , Pré-Escolar , Comorbidade , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Adulto Jovem
12.
Pharmacogenomics J ; 9(6): 362-72, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19652663

RESUMO

Ethnicity can confound results in pharmacogenomic studies. Allele frequencies of loci that influence drug metabolism can vary substantially between different ethnicities and underlying ancestral genetic differences can lead to spurious findings in pharmacogenomic association studies. We evaluated the application of principal component analysis (PCA) in a pharmacogenomic study in Canada to detect and correct for genetic ancestry differences using genotype data from 2094 loci in 220 key drug biotransformation genes. Using 89 Coriell worldwide reference samples, we observed a strong correlation between principal component values and geographic origin. We further applied PCA to accurately infer the genetic ancestry in our ethnically diverse Canadian cohort of 524 patients from the GATC study of severe adverse drug reactions. We show that PCA can be successfully applied in pharmacogenomic studies using a limited set of markers to detect underlying differences in genetic ancestry thereby maximizing power and minimizing false-positive findings.


Assuntos
Biotransformação/genética , Etnicidade/genética , Genética Populacional , Farmacogenética/métodos , Povo Asiático/genética , População Negra/genética , Canadá , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Frequência do Gene , Estudo de Associação Genômica Ampla , Humanos , Polimorfismo de Nucleotídeo Único , Análise de Componente Principal , População Branca/genética
13.
Ann Pharmacother ; 43(4): 586-95, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19336655

RESUMO

BACKGROUND: Contemporary studies document the outcomes of unfractionated heparin (UFH), enoxaparin, fondaparinux, and bivalirudin in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). It remains unclear which anticoagulant regimen is the most cost-effective. OBJECTIVE: To perform a cost-effectiveness analysis comparing 4 anticoagulant regimens in NSTE-ACS. METHODS: A decision analysis was conducted from a healthcare provider perspective. Data sources included the SYNERGY, OASIS-5, and ACUITY trials, including 2 subgroup analyses. A decision tree model was created incorporating the outcomes associated with 4 antithrombotic approaches: UFH with eptifibatide, enoxaparin with eptifibatide, bivalirudin alone, and fondaparinux with eptifibatide. The percentage of eptifibatide use in each arm was consistent with clinical trials. Probabilities of complications (eg, myocardial infarction, revascularization, major/minor bleeding at 30 days) were calculated. Costs were assigned to each outcome, incorporating the cost associated with diagnosis-related group and/or current procedural terminology codes, drug acquisition, and red blood cell infusions. Multiple sensitivity analyses were performed. RESULTS: The base case analysis showed bivalirudin monotherapy to be the least costly regimen ($1131 per average course), and it dominated enoxaparin plus eptifibatide ($1609) and UFH plus eptifibatide ($1739) in cost-effectiveness. The total average cost of fondaparinux with eptifibatide ($1184) was higher than bivalirudin alone, but the combination was more effective, resulting in an incremental cost of $2569 per each additional patient treated without complication. Sensitivity analyses showed the model's results to be sensitive to drug acquisition cost and complication probabilities. Probabilistic sensitivity analyses favored neither bivalirudin nor fondaparinux; however, when 2 or more vials of bivalirudin were necessary, bivalirudin was no longer a cost-effective alternative. CONCLUSIONS: Bivalirudin is the least costly agent in moderate- to high-risk NSTE-ACS patients managed with an early invasive approach, if its use is consistent with the ACUITY trial. Fondaparinux is the preferred agent in patients undergoing a conservative treatment strategy.


Assuntos
Síndrome Coronariana Aguda/economia , Anticoagulantes/economia , Síndrome Coronariana Aguda/tratamento farmacológico , Anticoagulantes/uso terapêutico , Análise Custo-Benefício , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/economia
14.
Stud Health Technol Inform ; 143: 209-14, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19380938

RESUMO

Adverse drug reactions (ADRs) are a major cause of morbidity and mortality in children. Current models of ADR surveillance have repeatedly demonstrated little pragmatic value to practicing clinicians. ADR reporting rates in the US and Canada suggest that only 5% of ADRs are reported. The Genotypic Approaches to Therapy in Children (GATC) network was established to identify and solve drug safety problems in paediatrics. We hypothesized that genetic polymorphisms underlie a significant portion of concentration-dependent ADRs in children. Our objective was to establish an ADR active surveillance network in paediatric hospitals across Canada. Surveillance clinicians evaluate clinical information from ADR cases and drug-matched controls, and collected DNA samples from all patients. The surveillance network will enable the identification of predictive genomic-markers for ADRs. With this knowledge, children at risk can be identified before therapy is initiated and enable personalized adjustments to therapy based on genetic make-up.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Farmacogenética , Canadá , Pré-Escolar , Genoma Humano/genética , Hospitais Pediátricos , Humanos , Informática Médica , Vigilância da População
15.
PLoS One ; 14(2): e0210646, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30763334

RESUMO

Childhood cancer patients treated with platinums often develop hearing loss and the degree is classified according to different scales globally. Our objective was to compare concordance between five well-known ototoxicity scales used for childhood cancer patients. Audiometric test results (n = 654) were evaluated longitudinally and graded according Brock, Chang, International Society of Pediatric Oncology (SIOP) Boston, Muenster scales and the U.S. National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE) version 4.03. Adverse effects of grade 2, 3 and 4 are considered to reflect a degree of hearing loss sufficient to interfere with day-to-day communication (> = Chang grade 2a; > = Muenster grade 2b). We term this "deleterious hearing loss". A total number of 3,799 audiograms were evaluated. The prevalence of deleterious hearing loss according to the last available audiogram of each patient was 59.3% (388/654) according to Muenster, 48.2% (315/653) according to SIOP, 40.5% (265/652) according to Brock, 40.3% (263/652) according to Chang, and 57.5% (300/522) according to CTCAEv4.03. Overall concordance between the scales ranged from ĸ = 0.636 (Muenster vs. Chang) to ĸ = 0.975 (Brock vs. Chang). Muenster detected hearing loss the earliest in time, followed by Chang, SIOP and Brock. Generally good concordance between the scales was observed but there is still diversity in definitions of functional outcomes, such as differences in distribution levels of severity of hearing loss, and additional intermediate scales taking into account losses <40 dB as well. Regardless of the scale used, hearing function decreases over time and therefore, close monitoring of hearing function at baseline and with each cycle of platinum therapy should be conducted.


Assuntos
Antineoplásicos/efeitos adversos , Carboplatina/efeitos adversos , Cisplatino/efeitos adversos , Perda Auditiva/induzido quimicamente , Neoplasias/tratamento farmacológico , Platina/efeitos adversos , Antineoplásicos/toxicidade , Audiometria , Carboplatina/toxicidade , Criança , Cisplatino/toxicidade , Feminino , Perda Auditiva/epidemiologia , Humanos , Masculino , Platina/toxicidade
16.
Crit Rev Oncol Hematol ; 126: 154-167, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29759558

RESUMO

INTRODUCTION: The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment. METHODS: A systematic literature search was performed, using Embase, Cochrane Library, Google Scholar, MEDLINE, and Web of Science databases. Eligible publications included all English language reports of candidate gene studies and genome wide association studies (GWAS) that aimed to identify genetic risk factors associated with the four late toxicities, defined as toxicity present after end of treatment. RESULTS: Twenty-seven articles were identified, including 26 candidate gene studies: metabolic syndrome (n = 6); BMD (n = 6); gonadal impairment (n = 2); hearing impairment (n = 12) and one GWAS (metabolic syndrome). Eighty percent of the genetic studies on late toxicity after childhood cancer had relatively small sample sizes (n < 200), leading to insufficient power, and lacked adjustment for multiple comparisons. Only four (4/26 = 15%) candidate gene studies had their findings validated in independent replication cohorts as part of their own report. CONCLUSION: Genetic susceptibility associations are not consistent or not replicated and therefore, currently no evidence-based recommendations can be made for hearing impairment, gonadal impairment, bone mineral density impairment and metabolic syndrome in CCS. To advance knowledge related to genetic variation influencing late toxicities among CCS, future studies need adequate power, independent cohorts for replication, harmonization of disease outcomes and sample collections, and (international) collaboration.


Assuntos
Sobreviventes de Câncer , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética , Variação Genética/fisiologia , Transtornos de Início Tardio/genética , Neoplasias/genética , Lesões por Radiação/genética , Densidade Óssea/genética , Sobreviventes de Câncer/estatística & dados numéricos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla , Humanos , Transtornos de Início Tardio/epidemiologia , Síndrome Metabólica/epidemiologia , Síndrome Metabólica/etiologia , Síndrome Metabólica/genética , Neoplasias/epidemiologia , Neoplasias/terapia , Lesões por Radiação/epidemiologia , Fatores de Tempo
17.
Transplantation ; 51(5): 1014-8, 1991 May.
Artigo em Inglês | MEDLINE | ID: mdl-2031258

RESUMO

To determine the effect of fluconazole on cyclosporine concentrations, we used a randomized, double-blind, placebo-controlled study design to evaluate 16 stable renal transplant recipients receiving a constant cyclosporine dose. The two groups of patients were given identical capsules of either placebo or fluconazole 200 mg daily for 14 days. Compliance with the protocol was ensured by watching each patient take all the drug doses. Frequent whole-blood cyclosporine trough concentrations, measured by high-performance liquid chromatography, and two area under the blood concentration time curves were determined before and after 14 days of fluconazole or placebo. The results show that cyclosporine trough concentrations, in patients given fluconazole, increased from a mean +/- SD of 27 +/- 16 to 58 +/- 28 ng/ml (P = 0.001) while patients given placebo did not change--35 +/- 26 vs. 37 +/- 35 ng/ml (P = 0.7). Mean cyclosporine AUC increased in the fluconazole patients from 2167 +/- 1039 to 3989 +/- 1675 ng.hr/ml (P = 0.02) while the placebo patients did not change, 3089 +/- 2439 vs. 2954 +/- 2216 ng.hr/ml (P = 0.9). The pre- and post-treatment cyclosporine AUC difference (day 16 minus day 2) for fluconazole vs. placebo was 1822 +/- 1083 vs. -134 +/- 831 ng.hr/ml (P = 0.001). Mean cyclosporine clearance decreased an average of 55% in the fluconazole patients from 1.2 +/- 0.5 to 0.7 +/- 0.4 ml/hr.kg (P = 0.03); the placebo patients did not change--1.4 +/- 1.1 vs. 1.7 +/- 2.3 ml/hr.kg (P = 0.07). During the study period, serum creatinine concentrations did not increase after fluconazole vs. placebo treatment; they were 1.4 +/- 0.3 vs. 1.3 +/- 0.3 mg% (P = 0.8) initially, and 1.4 +/- 0.2 vs. 1.3 +/- 0.3 mg% (P = 0.5) after 14 days. This study indicates that fluconazole 200 mg daily can slowly increase cyclosporine concentrations over two weeks of therapy, approximately doubling the cyclosporine trough concentrations. The management of this interaction requires prospective planning for adjustments in the cyclosporine dosage, guided by cyclosporine concentrations, while transplant recipients are receiving fluconazole.


Assuntos
Ciclosporinas/sangue , Fluconazol/farmacologia , Transplante de Rim , Adolescente , Adulto , Idoso , Interações Medicamentosas , Feminino , Fluconazol/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Transplante Homólogo
18.
Pharmacotherapy ; 16(4): 537-46, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8840360

RESUMO

The Internet is an excellent source of drug and poison information. Despite the relative case and minimal costs associated with accessing the Internet, many pharmacists and other health care professionals have been slow to adopt this new technology.


Assuntos
Redes de Comunicação de Computadores/organização & administração , Serviços de Informação sobre Medicamentos/organização & administração , Sistemas de Gerenciamento de Base de Dados , Humanos , Informática Médica , Intoxicação
19.
Pharmacotherapy ; 16(5): 879-88, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8888083

RESUMO

Health-related quality of life (HRQOL) is an important dimension in assessing health care. Several methodologic considerations are related to the manner in which these data are obtained in children. Few multidimensional generic measures of quality of life (QOL) have been developed for children and adolescents. Most published research concerns the development of tools to be used in a disease-specific manner for clinical trials. Although several authors point out numerous advantages in assessing HRQOL in clinical practice, several barriers must be overcome for this to occur. In the current era of economic restraint, HRQOL measures must be integrated into pharmaco-economic analyses to assess fully the impact of a drug on health care resources and outcomes.


Assuntos
Tratamento Farmacológico/economia , Avaliação de Resultados em Cuidados de Saúde , Qualidade de Vida , Adolescente , Criança , Pré-Escolar , Humanos , Lactente , Recém-Nascido
20.
Pharmacotherapy ; 16(5): 806-18, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8888076

RESUMO

The Internet is a potential source of information for practitioners and researchers of pharmaceutical sciences. Despite its explosive growth and popularity, pharmacists and other health care providers have been slow to use the Internet as a source of clinical information. We have identified and evaluated several sites available on the Internet that are devoted to providing information related to professional practice, pharmacotherapy, and toxicology. We have concerns, however, regarding the quality of the available information and advise users to be cautious in using the data they obtain.


Assuntos
Redes de Comunicação de Computadores/organização & administração , Serviços de Informação sobre Medicamentos/organização & administração , Estudos de Avaliação como Assunto , Sistemas de Informação , Informática Médica , Intoxicação , Controle de Qualidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA